Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUNDSystemic administration of adeno-associated virus (AAV) can trigger life-threatening inflammatory responses, including thrombotic microangiopathy (TMA), acute kidney injury due to atypical hemolytic uremic syndrome-like complement activation, immune-mediated myocardial inflammation, and hepatic toxicity.METHODSWe describe the kinetics of immune activation following systemic AAV serotype 9 (AAV9) administration in 38 individuals following 2 distinct prophylactic immunomodulation regimens. Group 1 received corticosteroids and Group 2 received rituximab plus sirolimus in addition to steroids to prevent anti-AAV antibody formation.RESULTSGroup 1 participants had a rapid increase in immunoglobulin M (IgM) and IgG. Increase in D-dimer, decline in platelet count, and complement activation are indicative of TMA. All Group 1 participants demonstrated activation of both classical and alternative complement pathways, as indicated by depleted C4 and elevated soluble C5b-9, Ba, and Bb antigens. Group 2 patients did not have a significant change in IgM or IgG and had minimal complement activation.CONCLUSIONSThis study demonstrates that TMA in the setting of AAV gene therapy is antibody dependent (classical pathway) and amplified by the alternative complement pathway. Critical time points and interventions are identified to allow for management of immune-mediated events that impact the safety and efficacy of systemic gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, levels of complement proteins associated with classical (C3a, C4a, C5a) and alternative (Ba, Bb) pathways along with terminal complement complex SC5b-9 were found to be elevated in patients who only received corticosteroids.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical studies in patients with Duchenne muscular dystrophy (DMD), where seronegative patients were administered with high dose AAV, suggest that IgM formation could still cause significant immunotoxicities.88,89”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Patients receiving only corticosteroids had increased levels of IgM and IgG on days 5 and 7, respectively.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Salabarria et al. evaluated the kinetics and effects of immune modulation on complement activation in groups of patients who received high systemic doses of AAV989.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
In the citing paper
“Based on these findings, the authors proposed that in humans, the classical pathway is critical for the initiation of complement activation and the occurrence of associated pathologies/toxicities following high-dose systemic delivery of AAV, whereas the alternative pathway may serve as an amplification loop.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444 · cited 2×
“A previous in vitro study showed that complement activation is observed with all adenovirus serotypes tested, including serotypes 1, 3, 4, and 9 (39).”
BackgroundSingle-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381 · cited 2×
“A previous in vitro study showed that complement activation is observed with all adenovirus serotypes tested, including serotypes 1, 3, 4, and 9 (39).”
BackgroundImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 1×
“AAV exposure can trigger the complement system, an innate defensive mechanism that induces rapid destruction of pathogens and acts as a functional sensor of the surface area of invading particles (17–19).”
BackgroundImmune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788 · cited 1×
“The activation of the innate and adaptive immunologic responses after de novo exposure to AAV, as well as humoral and cellular responses to pre-existing host immunity, are some of the primary barriers to the expanded use of these therapies (8–10).”
BackgroundSelf-citationCurrent clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Self-citationComplement and Its Receptors: New Insights into Human Disease
Holers, V. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120154 · Cited by 430 · cited 1×
“The complement system is composed of more than 30 proteins that play important roles in recognition and elimination of pathogens (20).”
BackgroundDifferential activation of innate immune responses by adenovirus and adeno-associated virus vectors
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., & Muruve, D. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4580-4590.2002 · Cited by 394 · cited 1×
“Importantly, Group 1 showed activation of the complement system, as demonstrated by reduction in C3 and C4, as well as increased C3a, C4a, C5a, Ba, Bb, and SC5b-9 AAV capsid proteins (alternative pathway) (8, 11, 21).”
BackgroundHuman Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357 · cited 1×
“A previous in vitro study showed that complement activation is observed with all adenovirus serotypes tested, including serotypes 1, 3, 4, and 9 (39).”
BackgroundZhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330 · cited 1×
“AAV particles are a potent activator of the innate immune system, not only through the physical properties of the capsid particle, but also through the response to the high capsid protein load associated with systemic AAV administration (11–13).”
BackgroundThe good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 286 · cited 1×
“C5b binds to C6, C7, C8, and C9 to generate the soluble C5b-9 (SC5b-9) membrane attack complex (MAC), leading to cell lysis and cell death (17, 24).”
BackgroundHumoral immune response to AAV
Calcedo, R., & Wilson, J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00341 · Cited by 243 · cited 2×
“A previous in vitro study showed that complement activation is observed with all adenovirus serotypes tested, including serotypes 1, 3, 4, and 9 (39).”
BackgroundThe Role of Complement in Liver Injury, Regeneration, and Transplantation
Thorgersen, E. B., Barratt‐Due, A., Haugaa, H., Harboe, M., Pischke, S. E., Nilsson, P. H., & Mollnes, T. E. (2019) · Hepatology · doi:10.1002/hep.30508 · Cited by 240 · cited 1×
“Both C5a and MAC can cause acute hepatic and myocardial injury (25).”
BackgroundOvercoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212 · cited 3×
“…AAV are recognized via the adaptor proteins, Toll-like receptors (TLRs), primarily TLR2 and TLR9, which can trigger an innate immune response and promote the activation of adaptive immunity through activation of cytokines and interferons (IFNs) that in turn activate CD8 + T cells (8, 12, 14, 15).”
BackgroundChand, D. H., Zaidman, C., Arya, K., Millner, R., Farrar, M. A., Mackie, F. E., Goedeker, N. L., Dharnidharka, V. R., Dandamudi, R., & Reyna, S. P. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.11.054 · Cited by 210
Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192 · cited 1×
“However, while these therapies offer a new approach to treat devastating diseases, the immunologic responses to AAV vectors pose a unique challenge that affects their safety and efficacy (5–7).”
BackgroundComplement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors
Zaiss, A. K., Cotter, M. J., White, L. R., Clark, S. A., Wong, N. C. W., Holers, V. M., Bartlett, J. S., & Muruve, D. A. (2008) · Journal of Virology · doi:10.1128/jvi.01990-07 · Cited by 177 · cited 3×
“Importantly, Group 1 showed activation of the complement system, as demonstrated by reduction in C3 and C4, as well as increased C3a, C4a, C5a, Ba, Bb, and SC5b-9 AAV capsid proteins (alternative pathway) (8, 11, 21).”
BackgroundAdeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy
Guillou, J., de Pellegars, A., Porcheret, F., Frémeaux-Bacchi, V., Allain-Launay, E., Debord, C., Denis, M., Péréon, Y., Barnérias, C., Desguerre, I., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006419 · Cited by 166 · cited 6×
“Participants in Group 1A (SMA) and 2A (SMA) received prophylactic oral prednisone (1 mg/kg/d) 1 day prior to AAV gene therapy administration and continued for 4 weeks after infusion as per the drug insert with consecutive tapering per clinician’s discretion over 4 to 8 weeks.”
BackgroundInfluentialVogelpoel, L. T. C., Baeten, D. L. P., de Jong, E. C., & den Dunnen, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00079 · Cited by 146 · cited 1×
“Fc γ RIIa is the main cytokine-inducing receptor in humans, which influences activation of TLR9, resulting in the production of IFN-α as well as other cytokines and chemokines such as TNF-α , IL-1 β , IL-6, and IL-8 (16).”
BackgroundImmunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136 · cited 3×
“…AAV are recognized via the adaptor proteins, Toll-like receptors (TLRs), primarily TLR2 and TLR9, which can trigger an innate immune response and promote the activation of adaptive immunity through activation of cytokines and interferons (IFNs) that in turn activate CD8 + T cells (8, 12, 14, 15).”
BackgroundSchulz, M., Levy, D. I., Petropoulos, C. J., Bashirians, G., Winburn, I., Mahn, M., Somanathan, S., Cheng, S. H., & Byrne, B. J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.010 · Cited by 125 · cited 11×
“Complement activation by AAV is primarily antibody dependent (classical pathway), triggered by anti-capsid IgM and IgG antibodies that can cause complement-mediated cell damage (18).”
BackgroundInfluentialSelf-citationComplement activation by recombinant adenoviruses
Cichon, G., Boeckh-Herwig, S., Schmidt, H., Wehnes, E., Müller, T., Pring-Akerblom, P., & Burger, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301611 · Cited by 123 · cited 2×
“A previous in vitro study showed that complement activation is observed with all adenovirus serotypes tested, including serotypes 1, 3, 4, and 9 (39).”
BackgroundAdeno-Associated Virus (AAV) Versus Immune Response
Rabinowitz, J., Chan, Y. K., & Samulski, R. J. (2019) · Viruses · doi:10.3390/v11020102 · Cited by 122 · cited 1×
“…AAV are recognized via the adaptor proteins, Toll-like receptors (TLRs), primarily TLR2 and TLR9, which can trigger an innate immune response and promote the activation of adaptive immunity through activation of cytokines and interferons (IFNs) that in turn activate CD8 + T cells (8, 12, 14, 15).”
BackgroundClinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
Day, J. W., Mendell, J. R., Mercuri, E., Finkel, R. S., Strauss, K. A., Kleyn, A., Tauscher-Wisniewski, S., Tukov, F. F., Reyna, S. P., & Chand, D. H. (2021) · Drug Safety · doi:10.1007/s40264-021-01107-6 · Cited by 119 · cited 1×
“…likely due to cytokine release, participants presented with complement-mediated thrombotic microangiopathy (CM-TMA) (31), acute kidney injury due to atypical hemolytic uremic syndrome–like (aHUS-like) complement activation, thrombocytopenia, and immune-mediated myocardial injury (28, 31–33).”
BackgroundChallenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes
Hamilton, B. A., & Wright, J. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675897 · Cited by 117 · cited 1×
“Complement activation by AAV is primarily antibody dependent (classical pathway), triggered by anti-capsid IgM and IgG antibodies that can cause complement-mediated cell damage (18).”
BackgroundCapsid-specific removal of circulating antibodies to adeno-associated virus vectors
Bertin, B., Veron, P., Leborgne, C., Deschamps, J.-Y., Moullec, S., Fromes, Y., Collaud, F., Boutin, S., Latournerie, V., van Wittenberghe, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57893-z · Cited by 100
Tian, J., Xu, Z., Smith, J. S., Hofherr, S. E., Barry, M. A., & Byrnes, A. P. (2009) · Journal of Virology · doi:10.1128/jvi.00082-09 · Cited by 88 · cited 1×
“Zaiss et al. demonstrated that AAV capsid particles interact with the complement proteins C3, C3b, iC3b, and complement regulatory factor H (11, 12, 22, 23).”
BackgroundFriese, J., Geitmann, S., Holzwarth, D., Müller, N., Sassen, R., Baur, U., Adler, K., & Kirschner, J. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200593 · Cited by 73
TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy
Ashley, S. N., Somanathan, S., Giles, A. R., & Wilson, J. M. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103997 · Cited by 67
Loo, L., Harris, S., Milton, M., Meena, M., Lembke, W., Berisha, F., Bertholet, S., Dessy, F. J., Dodge, R. W., Fang, X., et al. (2022) · Bioanalysis · doi:10.4155/bio-2022-0081 · Cited by 41
Galletta, F., Cucinotta, U., Marseglia, L., Cacciola, A., Gallizzi, R., Cuzzocrea, S., Messina, S., Toscano, A., & Gitto, E. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13733 · Cited by 35
Considerations for Systemic Use of Gene Therapy
Byrne, B. J., Corti, M., & Muntoni, F. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.016 · Cited by 23 · cited 1×
“Systemic gene therapy is one of the few medical therapies devised to date, akin to solid organ transplant, that cannot be reversed (41), therefore access to detailed safety data will help establish best practices and improve the safety of this transformative therapy.”
BackgroundSelf-citationWitte, D., Hartmann, H. P., Drube, J., Haffner, D., & Illsinger, S. (2021) · Klinische Pädiatrie · doi:10.1055/a-1538-4936 · Cited by 15
Byrne, B. J., Elder, M. E., Leon‐Astudillo, C., & Corti, M. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.007 · Cited by 15 · cited 1×
“The finding of acquired hemophagocytic lymphohistiocytosis following Zolgensma therapy further demonstrates the broad impact of systemic AAV on immune activation (36, 37).”
BackgroundSelf-citationAhmad, A., Mandwie, M., Dreismann, A. K., Smyth, C. M., Doyle, H. J., Malik, T. H., Pickering, M. C., Lachmann, P. J., Alexander, I. E., & Logan, G. J. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.022 · Cited by 11 · cited 1×
“Zaiss et al. demonstrated that AAV capsid particles interact with the complement proteins C3, C3b, iC3b, and complement regulatory factor H (11, 12, 22, 23).”
Background
Research works printed but not linked: 2
- Solid Biosciences. Solid Biosciences Provides SGT-001 Program Update. https://www.solidbio.com/about/media/press-releases/solid-biosciences-provides-sgt-001-program-update Updated November 12, 2019. Accessed November 1, 2023
- Pfizer. Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (dmd) Support Advancement into Pivotal Phase 3. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-new-phase-1b-results-gene-therapy-ambulatory-boys Updated May 15, 2020. Accessed November 2, 2023
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“418 The collective evidence seems to suggest that complement activation in rAAV infusion occurs through the classical pathway.”
BackgroundCurrent clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 163
“…after dosing, 12 demonstrated AAV is shed in semen for a duration that is vector dose dependent, 10,13,14 and unmasked unexpected immunological responses to AAV that have been expanded in subsequent studies 5,6,15–21 and continue to pose safety and efficacy limitations to AAV gene therapy.”
Self-citationPhase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease
Greenberg, B., Taylor, M. R. G., Adler, E. A., Colan, S. D., Ricks, D., Yarabe, P., Battiprolu, P. K., Shah, G., Patel, K., Coggins, M. P., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2412392 · Cited by 112
Self-citationInnate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50
“88,89 90 – 92 Clinical symptoms that may be related to complement activation included thrombotic microangiopathy (TMA), acute kidney injury involving atypical hemolytic uremic syndrome, thrombocytopenia, elevated transaminases, and endothelial injury.”
Self-citationSystemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice
Zhou, Y., Zhang, C., Xiao, W., Herzog, R. W., & Han, R. (2024) · Nature Communications · doi:10.1038/s41467-024-50569-6 · Cited by 51
“Encouragingly, a recent study from clinical trials showed that it is possible to prevent antibody response to AAV gene therapy by a cocktail of immune modulators (for example, rituximab plus sirolimus in addition to steroids) to prevent anti-AAV antibody formation 53 .”
Self-citation
Metadata
- Authors
- Salabarria, S. M., Corti, M., Coleman, K. E., Wichman, M. B., Berthy, J. A., D’Souza, P., Tifft, C. J., Herzog, R. W., Elder, M. E., Shoemaker, L. R., Leon-Astudillo, C., Tavakkoli, F., Kirn, D. H., Schwartz, J. D., & Byrne, B. J.
- Affiliations
- University of Florida Health (US)
- National Institutes of Health (US)
- Indiana University South Bend (US)
- Corresponding author
- Byrne, Barry J.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2024-01-02
- Volume
- 134
- Issue
- 1
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC10760971
- OpenAlex
- W4388860142
- Cited by
- 159
- References
- 35
- Citations by year
- 2026: 59 · 2025: 55 · 2024: 44
- FWCI
- 26.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- College of Medicine, University of Florida (HD052682)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- thrombotic microangiopathy, AAV9, AAV gene therapy, complement activation, classical complement pathway, alternative complement pathway, rituximab, rapamycin, corticosteroids, immunomodulation, D-dimer, atypical hemolytic uremic syndrome, immune-mediated toxicity
- MeSH terms
- Dependovirus, Humans, Immunoglobulin G, Immunoglobulin M, Thrombotic Microangiopathies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.